Kintara Therapeutics Advances with TuHURA Merger and Trials

Kintara Therapeutics ( (KTRA) ) just unveiled an update.

Kintara Therapeutics, Inc. has provided updates on its corporate progress and the REM-001 clinical study, announcing a definitive merger agreement with TuHURA Biosciences, Inc. The merger aims to create a stronger entity with promising cancer therapies, including REM-001 for cutaneous metastatic breast cancer, which lacks current effective treatments. Kintara urges shareholders to vote on the upcoming Special Meeting to approve the merger, which is crucial for the company’s financial stability and continued research efforts. Additionally, TuHURA is advancing a Phase 3 trial for an immuno-oncology product, potentially enhancing the combined company’s portfolio.

For an in-depth examination of KTRA stock, go to TipRanks’ Stock Analysis page.